Articles & Video
Can payment models for gene therapies evolve fast enough to keep up?
Gene therapy is revolutionizing healthcare, but can we revolutionize payment models in time to keep up?
HCEI and PIE: Is it time for pharma to be proactive in the argument over cost effectiveness?
How can drug manufacturers embracing the FDA's new HCEI and PIE guidance to engage payer customers early? Jeremy Schafer, PharmD, MBA, SVP, Precision for Value explores.
"There is always something interesting behind a state's motivation to control prescription drug costs" - Q&A with Porzio Life Sciences
Jennifer A. Romanski, JD, Vice President and Sara R. Simon, JD, Compliance Associate at Porzio Life Sciences discuss interesting legislation coming related to State Price Transparency in this exclusive interview.
What does it mean to be patient centered in health economics?
As the movement towards more patient-centered health care gains momentum, how does health economics sit at this intersection between cost-effective care and patient-centered care?
The evolution and challenges of State Price Transparency Reporting laws | Al Godley, ClassOne Insight
We spoke to Al Godley, VP of Customer Solutions at ClassOne Insight, about State Drug Price Transparency Laws and Reporting - the future, evolution and hurdles of the laws.
"Contracting will be the biggest innovation, but how it is actually implemented will be a challenge" - Cathy Burton-Meza, Gilead
"I see the very real possibility of value based contracting becoming more mainstream for drug manufacturers"
We spoke to Miree Lee, MS, MBA, Bio/Pharma Pricing, Contracts & Compliance Consultant, M. Lee Consulting, about how the new US administration will impact the industry and what changes she expects to see in the future.
SURVEY: Diversity, Equity and Inclusion in the Life Sciences 2021
Complete our survey on Diversity, Equity and Inclusion in the Life Sciences 2021 to get exclusive early access to the final report.
Pricing & Reimbursement US 2020
Whether a drug product is covered, and at what price, is determined by each payer’s coverage, coding, and payment criteria for health insurance plans. The largest government-funded
programs are Medicare and Medicaid, under which plans are subject to detailed requirements set forth by statute or regulation.
The 340B Drug Discount Program: Complexity, Challenges, and Change
This article describes how the 340B program works, the challenges it creates when it doesn’t, how it’s evolving, and possible strategies to mitigate its impact on gross-to-net.
Pharma’s role in maintaining cancer mortality progress during COVID-19
COVID-19 is threatening the progress made in reducing cancer mortality. Pharma has a pivotal role to play in helping patients and providers navigate the new reality of cancer treatment during the pandemic, and beyond.
Modeling SDOH financial sustainability
Discover how design thinking can be used to develop a financially sustainable model of Social Determinants of Health (SDOH).
Driving value in the era of biosimilars - What payers & manufacturers can do to support employers
We look at how big US employers are fostering broader adoption of biosimilar medications and what payers and manufacturers can do to support them.
REPORT: The Future of Healthcare Post COVID-19
In our latest report learn how healthcare organizations are adapting to succeed post COVID-19, from innovation to product development.
SURVEY: Partnering and Deal-Making in Biopharma through the Pandemic
We are conducting a huge study to gauge perspectives around biopharma deal-making during COVID-19 and the commercial ramifications of the pandemic. Take part here.
COVID-19 Report: The Response to and Impacts on the Global Life Sciences Industry
COVID-19 Report: How is the life sciences industry developing a vaccine, treatment and testing for COVID-19 and what impact is it having on supply chain?
Life Sciences in 2030 Survey: Complete to win a 2-day conference pass
We are a conducting a huge survey of life sciences professionals around the world on how the industry will look by 2030. Complete it here to get early access to the final report.
Why gene therapy lotteries are good for patients, providers, and manufacturers
Jeremy Schafer, PharmD, MBA argues how drug lotteries like Novartis' new program could mean a fairer and more beneficial system for all.
Does Zolgensma’s success predict similar rapid uptake of gene therapy for Hemophilia?
Doe the success of Zolgensma mean payers will be as welcoming to the cost and volume of hemophilia gene therapy or will payers wait for competition?